332 studies on GLP-1R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
The persistent cognitive dysfunction in Major Depressive Disorder (MDD) represents a significant burden for patients, often not adequately addressed by standard antidepressants. Semaglutide, a GLP-1 receptor agonist (…
This study is significant because it explores a novel application of GLP-1 receptor agonists beyond their established roles in diabetes and obesity, potentially positioning them as tools for proactive health optimizat…
This research is significant because it investigates a potential new benefit of tirzepatide beyond weight management and metabolic improvement: reducing breast cancer risk. Given the strong link between obesity and br…
Understanding how GLP-1RAs and GIP/GLP-1-dual agonists affect ocular blood flow and retinal health is critically important given their widespread use in diabetes management. If these medications demonstrate a benefici…
If liraglutide proves effective in improving lung function, it would represent a significant pleiotropic benefit beyond its established role in glucose control and weight management for Type 2 Diabetes Mellitus patien…
This study is critically important because it addresses a significant unmet medical need for effective treatments for cognitive dysfunction in individuals with type 2 diabetes, a population at high risk for dementia. …
Obstructive sleep apnoea significantly impacts quality of life and carries substantial health risks, particularly in obese populations. Liraglutide, a GLP-1 analogue, is already approved for weight management and type…
This multicentre, non-interventional study provides invaluable real-world evidence on Liraglutide (Saxenda®) safety and effectiveness, which is critical for understanding its performance outside of controlled clinical…
This trial design is significant because chronic heart failure and type 2 diabetes represent a substantial global health burden, and understanding how GLP-1 (glucagon-like peptide-1) agonists impact cardiac function c…
This study highlights the potential for IDegLira to significantly improve the quality of life for very old patients with Type 2 Diabetes by streamlining their treatment. Simplifying medication regimens can enhance adh…
This Phase 3 trial is a critical step in evaluating CagriSema as a potentially more potent treatment for obesity and type 2 diabetes than current GLP-1 monotherapies. The large enrollment of 2500 participants and exte…
This research is crucial as it expands the understanding of GLP-1 RA efficacy beyond weight-centric applications, particularly for a patient population where weight loss might not be a primary goal or even desirable. …
A successful semaglutide nasal spray could offer a more convenient and potentially less invasive administration route for patients managing overweight or obesity. This novel delivery method could significantly improve…
Reducing NETosis could represent a novel therapeutic strategy for managing inflammation and progression in diabetic kidney disease and immune-mediated kidney diseases. Identifying specific drug classes like SGLT2 inhi…
This research is crucial for understanding the precise behavioral mechanisms through which GLP-1 receptor agonists promote weight loss, moving beyond self-reported data to direct observation. The identification of spe…
This study is crucial for understanding how Semaglutide performs in a diverse patient population under typical healthcare conditions, rather than idealized trial environments. Real-world evidence complements tradition…
This research is significant because it addresses a critical health disparity, focusing on Mexican American women who are at elevated risk for type 2 diabetes. Improving beta cell function is a direct strategy to halt…
Understanding the link between neuropathy and semaglutide-induced gastric retention is crucial for optimizing patient care and safety. This research could lead to improved risk stratification for diabetic patients con…
The successful completion of a bioequivalence study is a critical step in the drug development process, particularly for generic versions or new formulations of existing medications. Demonstrating bioequivalence means…
This narrative review is crucial because it synthesizes the current understanding of GLP-1 RAs, suggesting they could be a valuable therapeutic strategy for improving the long-term health of cancer survivors. Given th…
The potential for Liraglutide to address both nicotine dependence and weight management simultaneously is significant, as weight gain is a common barrier to successful smoking cessation. This dual-action approach coul…
This Phase 4 clinical trial provides robust evidence reinforcing that liraglutide, a GLP-1 receptor agonist, is effective in reducing systolic blood pressure in patients with Type 2 diabetes and co-existing hypertensi…
This Phase 1 trial is crucial for understanding the fundamental mechanisms by which liraglutide exerts its metabolic effects in obese individuals, even without specific outcome data in the abstract. By clarifying its …
This Phase 3 study is critical because it directly compares two of the most promising pharmacological approaches for obesity management, potentially establishing a new standard of care. The results will provide invalu…
This study is crucial because it addresses a highly underserved patient group: individuals with severe obesity and multimorbidity who cannot undergo bariatric surgery. The findings could establish a new, effective tre…
Understanding the specific metabolic changes induced by CagriSema versus diet-induced weight loss is crucial for optimizing obesity treatment strategies. If CagriSema demonstrates superior or distinct metabolic benefi…
This study provides compelling evidence that semaglutide could be a groundbreaking treatment option for individuals struggling with Alcohol Use Disorder, particularly those with comorbid obesity. Given the high global…
The preservation of bone health during weight loss is a critical consideration, especially for postmenopausal women who are already susceptible to bone density loss and fracture risk. This study is significant because…
This study provides compelling evidence that GLP-1 medicines may offer substantial benefits beyond their primary role in weight loss and metabolic health. The observed improvements in mental health, eating disorder sy…
This review represents a conceptual shift in T2D management, proposing that cognitive preservation should become an explicit therapeutic objective, integrated with metabolic control. The identification of existing glu…
This study reveals a notable disparity in the utilization of GLP1RAs among individuals with multiple sclerosis who possess cardiometabolic comorbidities that would warrant such treatment. The findings underscore the i…
The findings from this study, once published, could significantly advance our understanding of GLP-1 agonists beyond weight loss, specifically in treating binge eating disorder. If Liraglutide proves effective, it cou…
This Phase III comparative trial is significant because it directly compares three different GLP-1 RA formulations, potentially providing crucial data to guide treatment selection for obese patients. The findings coul…
PCOS is a complex condition with significant unmet needs, particularly for obese and infertile women who struggle with its multifaceted symptoms. If liraglutide demonstrates superior or even comparable efficacy to met…
If successful, this line of research could reposition GLP-1 agonists as potential neuroprotective agents, expanding their therapeutic utility beyond metabolic disorders. The findings, had they been positive, could hav…
This foundational Phase 1 study was critical in establishing the initial safety and pharmacokinetic profile of liraglutide, a drug that later became a cornerstone in the treatment of Type 2 Diabetes and obesity. The p…
Understanding patient experience, especially regarding injection site pain, is crucial for improving adherence to long-term treatments for conditions like Type 2 Diabetes and obesity. If one GLP-1 agonist consistently…
The insights gleaned from this large-scale, multi-country observational study will be invaluable for understanding the real-world effectiveness and safety profile of semaglutide for weight management. This data will h…
This Phase 4 pragmatic trial is crucial because it provides real-world evidence on semaglutide's long-term performance against a broad spectrum of existing Type 2 Diabetes treatments. Such data helps clinicians and pa…
The successful completion of this Phase 1 safety and tolerability study is a pivotal step for LY3841136 and its potential role in obesity treatment. If LY3841136 proves to be safe and effective in combination with tir…
The findings from this study, once published, will be crucial for understanding the full therapeutic potential of incretin-based therapies beyond current GLP-1 receptor agonists. If the combined GIP and GLP-1 activati…